Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
One of the major challenges in the development of central nervous system (CNS)-targeted drugs is predicting CNS exposure in human from preclinical data. In this study, we present a methodology to investigate brain disposition in rats using a physiologically based modeling approach aiming at improving the prediction of human brain exposure. We specifically focused on quantifying regional diffusion and fluid flow processes within the brain. Acetaminophen was used as a test compound as it is not subjected to active transport processes. Microdialysis probes were implanted in striatum, for sampling brain extracellular fluid (ECF) concentrations, and in lateral ventricle (LV) and cisterna magna (CM), for sampling cerebrospinal fluid (CSF) concentrations. Serial blood samples were taken in parallel. These data, in addition to physiological parameters from literature, were used to develop a physiologically based model to describe the regional brain pharmacokinetics of acetaminophen. The concentration–time profiles of brain ECF, CSFLV, and CSFCM indicate a rapid equilibrium with plasma. However, brain ECF concentrations are on average fourfold higher than CSF concentrations, with average brain-to-plasma AUC0 − 240 ratios of 121%, 28%, and 35% for brain ECF, CSFLV, and CSFCM, respectively. It is concluded that for acetaminophen, a model compound for passive transport into, within, and out of the brain, differences exist between the brain ECF and the CSF pharmacokinetics. The physiologically based pharmacokinetic modeling approach is important, as it allowed the prediction of human brain ECF exposure on the basis of human CSF concentrations.
Authors and Affiliations
Joost Westerhout, Bart Ploeger, Jean Smeets, Meindert Danhof, Elizabeth C. M. de Lange
Keywords
Related Articles
- EP ID EP681239
- DOI 10.1208/s12248-012-9366-1
- Views 59
- Downloads 0
Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein–Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6
Disease-mediated therapeutic protein–drug interactions have recently gained attention from regulatory agencies and pharmaceutical industries in the development of new biological products. In this study, we develo...
A Quantitative Structure–Activity Relationship for Translocation of Tripeptides via the Human Proton-Coupled Peptide Transporter, hPEPT1 (SLC15A1)
The human intestinal proton-coupled peptide transporter, hPEPT1 (SLC15A1), has been identified as an absorptive transporter for both drug substances and prodrugs. An understanding of the prerequisites for transport has s...
Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution
Quantification of target site pharmacokinetics (PK) is crucial for drug discovery and development. Clinical micro-dialysis (MD) has increasingly been employed for the description of drug distribution and receptor phase P...
Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity—An Overview for Applied Toxicology
The online version of this article (doi:10.1208/s12248-011-9301-x) contains supplementary material, which is available to authorized users.
Opioid peptide-derived analgesics
Two recent developments of opioid peptide-based analgesics are reviewed. The first part of the review discusses the dermorphin-derived, cationic-aromatic tetrapeptide H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA, where Dmt indic...